Stelara was first approved in 2009 to treat psoriasis and psoriatic arthritis.
The anti-inflammatory drug, which posted $2.5 billion in sales for 2015, is one of New Brunswick, N.J.-based Johnson & Johnson’s biggest revenue generators.
The FDA based its approval on late-stage study results that show Stelara successfully treated patients with moderate-to-severe Crohn’s disease who did not respond to traditional medications.
More articles on supply chain:
Red Cross: Blood donations still needed to replenish supply
FDA approves handheld device to assess traumatic brain injury
Mylan underreported EpiPen profits by 60% at Congressional hearing
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
